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Abstract There is unmet need in patients suffering from
chronic pain, yet innovation may be impeded by the dif-
ficulty of justifying economic value in a field beset by data
limitations and methodological variability. A systematic
review was conducted to identify and summarise the key
areas of variability and limitations in modelling approaches
in the economic evaluation of treatments for chronic pain.
The results of the literature review were then used to
support the development of a fully flexible open-source
economic model structure, designed to test structural and
data assumptions and act as a reference for future mod-
elling practice. The key model design themes identified
from the systematic review included: time horizon; titration
and stabilisation; number of treatment lines; choice/order-
ing of treatment; and the impact of parameter uncertainty
(given reliance on expert opinion). Exploratory analyses
using the model to compare a hypothetical novel therapy
versus morphine as first-line treatments showed cost-ef-
fectiveness results to be sensitive to structural and data
assumptions. Assumptions about the treatment pathway
and choice of time horizon were key model drivers. Our
results suggest structural model design and data assump-
tions may have driven previous cost-effectiveness results
and ultimately decisions based on economic value. We
therefore conclude that it is vital that future economic
models in chronic pain are designed to be fully transparent
and hope our open-source code is useful in order to aspire
to a common approach to modelling pain that includes
robust sensitivity analyses to test structural and parameter
uncertainty.
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Introduction
Chronic pain has been defined as persistent pain, lasting at
least 3 months [1], and can present in the course of many
diseases, including cancer, trauma, neuropathy and
osteoarthritis [2]. The pharmaceutical treatment of chronic
pain is highly dependent on the needs of the individual
patient, the severity and frequency of their pain, and also on
local clinical practices. The overall approach to the treat-
ment and management of chronic pain is best considered
with reference to theWorld Health Organisation’s (WHO’s)
‘three-step’ ladder. The three-step ladder outlines the
movement of patients with uncontrolled chronic pain
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through various treatment stages, based on the use of:
standard oral analgesia (e.g. aspirin, paracetamol) or anti-
inflammatory drugs (e.g. non-steroidal anti-inflammatory
drugs); milder opioids (e.g. codeine, tramadol); and finally
the more potent stronger opioids (e.g. morphine, oxy-
codone, fentanyl) [3]. However, patients who suffer from
chronic pain continue to have unmet need [4]. In addition,
the treatment paradigm for the control of moderate to severe
chronic pain may be shifting towards a new wave of non-
opioid drug treatments that will sit outside of the standard
use of current opioid treatment options. As international
treatment standards for effective pain control continue to
develop, it will become increasingly important to be able to
appraise the cost-effectiveness of competing pain therapies
(both new and old) in a consistent, transparent and robust
way to understand the true value of these treatments.
While the attributes and management of specific dis-
eases associated with chronic pain, such as fibromyalgia
and osteoarthritis, and different analgesic requirements for
neuropathic versus other chronic pain may have justifiably
led to modelling heterogeneity, clinical differences
between the management of (1) malignant and (2) non-
malignant chronic pain have generally not warranted dif-
ferent approaches to economic evaluation. This study uses
the term chronic pain to describe pain of malignant or non-
malignant causation.1 Economic evaluations of pharma-
ceutical treatments in chronic pain have used modelling
approaches to justify price premiums for novel products,
but have faced a number of key hurdles and challenges in
how best to describe the overall treatment pathway for
patients. First, the nature of the individual drug treatments
can lead to difficulties in the management of adverse event
profiles, including but certainly not limited to the impact
from chronic constipation and severe nausea [5–7]. Side-
effect differences between therapies are not necessarily
powered for in clinical studies, making meaningful com-
parison difficult. Second, the efficacy of treatment is
extremely individualised and as such is difficult to assess
and categorise across patients. A significant proportion of
patients will be expected to achieve at best only a partial
control of their pain symptoms, even if treatments are well
tolerated. This level of expected variability in both the
adverse effect (AE) profile and pain response means that
treatment discontinuation, patient monitoring and treatment
switching (both across and within drug class) are all key
aspects of the ‘real-life’ clinical management of chronic
pain [8, 9]. These aspects need to be recognised and fully
considered when conducting evaluations of economic
value. Third, the designs of clinical trials are rarely based
on multiple lines of therapy and are also seen to apply strict
protocol-driven levels of adherence, which can ultimately
underestimate the scale of ‘real-life’ treatment discontin-
uation and switching. Finally, the equivalence design of
many clinical trials, with effectively unlimited dose titra-
tion, means that detecting any meaningful difference in
pain control (where patients have remained on therapy) is
extremely difficult to achieve.
All these factors may have led to variability and limi-
tations in the approaches and modelling structures used in
the economic evaluation of pharmaceutical treatments in
chronic pain. This may have restricted access to treatments
to patients in great need and in the longer term may dis-
courage innovation in novel analgesic therapies. The UK
National Institute for Health and Care Excellence (NICE)
has guidelines in place for opioid use in palliative care
[10], and the Guideline Development Group (GDG) were
critical of the potentially serious limitations of the previous
models they identified [6, 11, 12]. The challenges to eco-
nomic evaluation in this area that have led to variation in
modelling approaches may have also severely limited the
usefulness of findings from previous studies.
In this study we first conducted a systematic review of the
published economic literature to help identify, summarise
and explore the key areas of variability and limitations in the
modelling approaches used in economic evaluations of
treatments for chronic pain. The results of the literature
review were then used to support the development of a de
novo economic model structure. A full set of scenario and
sensitivity analyses were then conducted in order to high-
light and explore how such a model structure can be best
used to address the key areas identified in the systematic
review, where the care pathway may need to consider
treatment withdrawal and switching and where parameter
uncertainty remains because of a lack of robust data.
The de novo model structure can be potentially used as a
‘reference case’ for future economic models for pain
therapy and to guide future practice. To help with acces-
sibility and applicability to different country settings, an
effort has been made to make the model fully flexible and
transparent, with the open-source code (in the program-
ming language R) being provided as supplementary mate-
rial. This is intended to allow other researchers to easily
adapt and apply the model to further progress the devel-
opment of health economic models in pain therapy.
Methods and materials
Systematic review
The systematic literature review was designed to identify
peer-reviewed English language economic evaluations of
1 The different treatment pathway for chronic neuropathic pain
compared to other chronic pain means that it falls outside of the scope
of this study.
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oral, nasal or transdermal pharmacological treatments for
chronic pain, published since January 2000. The search
strategy was developed through a scoping exercise and
targeted the databases MEDLINE, EMBASE, Health
Technology Assessment, NHS Economic Evaluation
Database and EconLit. The scope of the review was eco-
nomic evaluations for which the pathway of chronic pain
treatment and not the nuances of a particular disease drove
the modelling approach. For this reason, though the search
strategy was broad, studies specific only to osteoarthritis,
low back pain, neuropathic pain, fibromyalgia and post-
surgery pain were excluded from the final review. All
searches were performed within the University of Shef-
field’s School of Health and Related Research (ScHARR)
during April 2014. Full details of the search strategy are
available as supplementary material.
Identified economic evaluations and model designs
The search identified 12 published relevant economic
evaluation studies [5–7, 10–18]. From these, eight original
model structures were identified [5–7, 10, 13, 15, 17, 18],
comprising one individual-level discrete event simulation
(DES) model [12] and seven cohort-level state-transition
(Markov) models. The most common country settings were
the UK [10, 13, 17] and Germany [11, 12, 15]; other
studies have been set elsewhere in Europe or the USA.
Studies identified in the review focussed on opioid-based
treatments, including regimens of morphine, oxycodone,
tapentadol, tramadol, oxycodone, fentanyl and buprenor-
phine, sometimes in combination with naloxone. Perhaps
due to non-inferiority trial designs for opioid trials, previ-
ous models have assumed an equal analgesic effect across
comparators and have captured differences in effectiveness
in terms of rates of withdrawal and adverse effects only.
The key features of the model designs used are sum-
marised in Table 1.
Though 5 of 12 studies reported systematic searches to
identify input data [6, 10, 12, 13, 18], in the absence of data
on key elements of the care pathway, previous studies have
been reliant on expert opinion to inform key parameter and
structural modelling decisions. This may have led to vari-
ation in structural design across the previous models. Some
authors, such as the NICE GDG [10], have favoured less
complex model designs, which reflect the availability of
robust data, while others have designed their model to be
sufficiently complex to capture care pathways.
Key design themes
Key model design decisions and variations across models
include: (1) the number of treatment lines considered; (2)
the choice of treatments across consecutive treatment
lines; and (3) the approach used to capture the initial
titration and stabilisation phase of opioid treatment.
Approaches to these decisions have varied across previous
studies, but no study has explored the implications of
uncertainty in their choice of modelling approach for
study findings. This is a key focus in the development of
the reference case de novo economic model structure
described in this study.
Expert opinion data are uncertain and analyses using
such data to inform cost-effectiveness estimates should
incorporate this uncertainty into their sensitivity analysis.
While previous models have reported deterministic and
probabilistic sensitivity analyses, the scale of uncertainty
assumed around expert parameter estimates may not have
been sufficiently wide to fully capture uncertainty.
Extrapolation of data over time also requires further
assumptions, and the consequences from the exact choice
of analytical time horizon has not always been robustly
tested in previous models.
In addition, future generations of pharmacological
therapies for chronic pain may offer analgesic improve-
ment, and previous models may not have been designed to
directly capture and reflect the value from such outcomes
(again with a focus on non-inferiority in efficacy driven
from clinical trial designs).
Derived from the systematic review of economic mod-
els, the key areas or model design themes for exploration in
this study can be summarised as follows:
1. time horizon;
2. titration and stabilisation;
3. number of treatment lines;
4. choice of treatment across consecutive treatment lines;
5. potential for value from analgesic improvement across
interventions;
6. implications of uncertainty around parameter estimates.
Reference model
Model transparency and coding
A flexible decision analytic model was initially pro-
grammed in Microsoft Excel to appraise competing
pharmacological treatments for chronic pain. The model
was then replicated in the program R [19] to validate the
model and to put it into a code-based format that can be
easily shared, hence allowing full transparency. To repli-
cate presentation of sensitivity analysis results the R
package ‘‘ggplot2’’ was used [20]. The model design was
based on findings and key themes identified from the sys-
tematic review, and the model was designed explicitly to
have the capacity to explore key areas of uncertainty. The
authors hope this model, which is referred to from here as
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the ‘reference model’, will be useful to practitioners as a
point of reference in guiding future model design in the
area, and the model is made freely available as supple-
mentary material in the form of R code. The model is also
presented as supplementary material without the full sen-
sitivity analysis code and in Microsoft Excel so it is readily
accessible and understandable to researchers new to the
model.
Model structure
In line with the majority of previous models [6, 7, 10,
13, 15, 17, 18], the reference model is a state-transition
Markov cohort model. The model structure has been
designed and built with sufficient complexity and flexi-
bility to consider the range of uncertainty in design
features identified through the systematic literature
review.
Though the care pathway for chronic pain may be
complex and heterogeneous, data limitations may preclude
meaningful benefit from discrete event or discrete indi-
vidual simulation approaches for contemporary chronic
pain models. In addition, the use of DES models in HTA
assessment is not universally supported by reimbursement
bodies and can create additional hurdles in decision mak-
ing. For this reason, the potential advantages from a DES
approach have not been considered within the design of the
reference model, primarily in order to retain a widely
applicable and adaptable model structure.
The reference model structure for one treatment arm is
illustrated by Fig. 1. Each model state is associated with a
cycle cost and utility value, and movements between model
states are determined by the model structure and input data.
A hypothetical cohort of patients with chronic pain enter
the model upon treatment initiation, while on first-line
treatment patients are distributed across two model states
depending on whether or not they are experiencing toler-
able treatment-related AEs.
Time horizon The time horizons adopted by previous
models have been similar and limited. All except one study
used a time horizon of 1 year or less and assumed zero
mortality. The remaining study used a 6-year time horizon,
but did not model treatment- or disease-related mortality
[15]. The study assessed opioid-related fractures as a key
health outcome and included consideration of the higher
incidence of death following fractures [15]. Only one
model [7] employed trial data with follow-up equal to the
model length; the majority of studies relied on assumptions
to extrapolate beyond trial endpoints, and the implications
of such assumptions for model results were not always
robustly tested. In line with previous models and in order to
accurately capture the available input data, the reference
model uses a cycle length of 1 week and a time horizon of
1 year as the base case.
Titration and stabilisation Some previous studies have
modelled the titration and stabilisation phase(s) as a
Fig. 1 Model structure—one treatment arm
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separate model state(s), typically lasting a month [6, 13] or
in one case 8 weeks [12]; others have not considered the
cost and health-related quality of life (HRQL) implications
of the initial stages of therapy [7, 10, 15, 17, 18], perhaps
because the implications of the titration and stabilisation
phase for model outcomes have been similar across treat-
ment arms when two or more opioids have been compared.
The model structure in Fig. 1 does not include a separate
state(s) for titration and stabilisation, but the model is
designed so that the cycle probabilities of withdrawal and
treatment costs can be adjusted for the first 4 weeks of first-
line treatment, allowing the importance of titration
assumptions to be tested in the structural sensitivity
analysis.
Withdrawal Treatment withdrawal is a feature of the
typical patient care pathway in chronic pain. Of the eight
unique published models structures identified in the liter-
ature review, six considered the health economic conse-
quences of treatment withdrawal [5–7, 10, 13, 18]. These
models varied however in the scope of reasons for with-
drawal and the assumptions on the subsequent management
of these patients.
In the reference model, patients may withdraw from
first-line treatment because of either: (1) intolerable AEs or
(2) other reasons including insufficient pain relief. Fol-
lowing one model cycle in either of the transitory states,
labelled ‘‘Withdrawal—AEs’’ and ‘‘Withdrawal—Other
(including pain)’’ in Fig. 1, patients either move to second-
line treatment or discontinue, in effect leaving the care
pathway. The model states for second-line treatment are
identical to those for first-line treatment; while on treat-
ment, patients may or may not experience tolerable treat-
ment-related AEs and patients may withdraw from second-
line treatment because of intolerable AEs or for other
reasons including insufficient pain relief.
Treatment lines/subsequent treatment The majority of
previous models (5 of 8) have captured outcomes for
multiple treatment lines [5–7, 10, 13], and the conse-
quences of treatment withdrawal and subsequent care are
greatly important for health and cost outcomes. The ref-
erence model was therefore designed with the capacity to
capture outcomes over multiple treatment lines. However,
as shown in Table 1, the number of treatment lines con-
sidered varied across previous models, and it was felt
important to test the effect of different structural assump-
tions in this area. Following second-line treatment with-
drawal, the reference model has the flexibility to either
assume all patients discontinue treatment or, as explored in
the scenario analysis and depicted in Fig. 1, assume a
proportion of patients move into an absorbing state repre-
senting subsequent treatment. The states ‘‘Subsequent
treatment’’ and ‘‘Treatment discontinuation’’ are the two
absorbing states in the model.
Model inputs
Treatment comparison/analysis perspective
In this exploratory analysis, the reference model is used to
compare a hypothetical newly developed oral therapy (re-
ferred to herein as the novel therapy) to a representative
comparator morphine. Morphine is widely used interna-
tionally as a reference treatment in the management of
chronic pain and recommended as a first-line treatment for
pain in palliative care in the UK [10]. The country setting
for three studies in the review was the UK [10, 13, 17] and
the perspective on costs in this study is that of the UK
National Health Service and Personal Social Services
(NHS and PSS) (the healthcare payer). Due to fact that
there were a number of UK models in the literature,
including an HTA, the UK was chosen as the example
country for the reference case. It is anticipated that the UK
example can be readily applied and adapted to other
geographies, particularly similar health systems within
Europe. The perspective on health outcomes is that of
direct health effects.
In the absence of robust evidence for second-line
treatment choice following withdrawal from morphine, the
model assumes second-line oral controlled-release oxy-
codone therapy across treatment arms, though morphine as
second-line treatment following novel therapy treatment is
also explored as a scenario.
Although morphine is recommended as a first-line
treatment for chronic pain in certain settings in the UK
[10], the more novel oral controlled-release oxycodone
has exhibited a preferable tolerability profile in compar-
ison to morphine in previous studies [12] and is increas-
ingly used internationally in clinical practice—often as
first-line therapy [13]. It is likely that a therapy entering
the market would exhibit superior efficacy in comparison
to the more effective drug, at a price premium. The
comparison assumes the hypothetical novel therapy is six
times as expensive and yields a 30 % improvement in
levels of tolerable AE rates and withdrawal rates versus
oxycodone.
Model inputs were sourced from the economic evalua-
tion studies identified in the systematic literature search.
The best available data for each model parameter were
sought from previous studies. These data provide an initial
basis to the de novo model and hypothetical exploratory
analysis and are a good indication of the available data in
this area. All model input estimates were validated by a UK
clinical expert. Due to the short time horizons considered,
model health outcomes and costs were not discounted. A
760 W. Sullivan et al.
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half-cycle correction was applied to cost and health
outcomes.
Adverse event and withdrawal rates
Table 2 describes the cycle probability estimates for tol-
erable AEs, withdrawal due to intolerable AEs or other
reasons, and treatment discontinuation used in the
exploratory analysis.
The cycle probabilities of tolerable AEs and withdrawal
rates attributable to morphine were calculated from data
reported by Greiner et al. [12], the most recent data
available for these parameters (also later used by Hauber
et al. [16]). The tolerable AEs considered in the reference
model are nausea/vomiting and chronic constipation.
Greiner et al. [12] reported 28-day rates for these AEs and
withdrawal rates because of AEs and other reasons (lack of
efficacy) separately for morphine patients. Following
Greiner et al. [12], a duration of 7 days for nausea/vomit-
ing is assumed. For chronic constipation, the duration of
adverse effects was not reported, and it is assumed that the
percentage of patients reported to experience mild chronic
constipation over 28 days was equivalent to the probability
of constipation with morphine in any model cycle. There
were no data on the proportion of patients who experienced
nausea/vomiting and constipation concurrently; it was
assumed that the cycle probabilities of each adverse event
are additive, resulting in a cycle probability of experienc-
ing tolerable AEs on morphine of 43.6 %, as shown in
Table 2.
The corresponding cycle probabilities for second-line
oxycodone were calculated from Ikenberg et al. [13], who
reported 105 day rates for (1) tolerable AEs, (2)
withdrawal because of AEs and (3) other reasons (lack of
efficacy) for a large sample of patients (n[ 1000)
receiving oxycodone as a second-line treatment. Though
patient numbers and transitions between health states were
clearly reported by Ikenberg et al. [13], details of the
duration of adverse effects were not clear. The cycle
probability of experiencing tolerable AEs on oxycodone
was assumed equivalent to the proportion of oxycodone
patients who experienced tolerable AEs over the 15-week
trial reported by Ikenberg et al. [13], 46.4 % as shown in
Table 2.
There is a risk of patients giving up on the care pathway
and discontinuing treatment rather than attempting alter-
native treatment options after a failed therapy, though data
on this risk are lacking in previous models. This explora-
tory analysis assumed a 5 % cycle probability of treatment
discontinuation treatment following first-line treatment
failure.
Resource use and cost estimates
Table 3 shows the cost data used in the model. All costs
have been inflated to 2013 values where appropriate [21].
Drug costs for morphine and oxycodone were taken from
the British National Formulary (BNF) 67 [22]. Following
NICE guidance [10], a maintenance dose of 60 mg mor-
phine per day was assumed, and the use of Morphgesic
SR, MST Continus, Zomorph and Filmarine SR (the
four modified-release 12-hourly oral preparations listed in
the BNF 67 [22]) was assumed to be evenly distributed.
Taking an unweighted average of pack prices for the pill
doses available up to 30 mg for each oral preparation, the
price of morphine therapy was calculated as £2.63 per
Table 2 Parameter estimates for cycle probabilities of tolerable AEs, treatment withdrawal and care discontinuation
Parameter description Estimate Source
Cycle probability tolerable AE, morphine 0.436 Calculated from [12]a
Cycle probability withdraw because of AE, morphine 0.056 Calculated from [12]b
Cycle probability withdraw because of other reason, morphine 0.013 Calculated from [12]b
Cycle probability tolerable AE, oxycodone 0.464 Calculated from [13]c
Cycle probability withdraw because of AE, oxycodone 0.033 Calculated from [13]d
Cycle probability withdraw because of other reason, oxycodone 0.002 Calculated from [13]d
Cycle probability tolerable AE, novel therapy 0.324 Assumption: proportional reduction of 0.3 relative to oxycodone
Cycle probability withdraw because of AE, novel therapy 0.023 Assumption: proportional reduction of 0.3 relative to oxycodone
Cycle probability withdraw because of other reason, novel therapy 0.002 Assumption: proportional reduction of 0.3 relative to oxycodone
Cycle probability discontinue after failed 1st-line treatment 0.050 Assumption
a Seven-day probability of nausea/vomiting calculated from 28-day rate plus assumed constant risk of constipation
b Seven-day probability calculated from midpoint of 28-day probability range
c Assumed constant risk of experiencing adverse effects from 105-day rate
d Seven-day probability calculated from 105-day probability
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week. Following Dunlop et al. [17], a maintenance dose of
32.2 mg oxycodone per day was assumed. The price of a
56-tab pack of generic oxycodone 10 mg is £22.86 and the
price per milligram does not vary by pill strength [22]; the
price of oxycodone therapy was therefore calculated as
£9.20 per week.
The weekly costs of concomitant laxatives to prevent
constipation while receiving morphine, as well as the cycle
cost associated with tolerable AEs, are those reported by
NICE [10], the only previous economic evaluation to
consider morphine for chronic pain from a UK NHS cost
perspective. Weekly concomitant drug costs for oxycodone
are those reported by Dunlop et al. [17], a recent UK study
that took a micro-costing approach to estimate the treat-
ment and concomitant medication costs associated with
oxycodone. The weekly cost of novel therapy treatment is
assumed to be six times the cost for oxycodone, while the
cost of concomitant laxatives is reduced by 30 % compared
to oxycodone. The one-off cost associated with withdrawal
is that used by NICE [10], comprising a general practi-
tioner (GP) surgery visit, 10 min with a medical consultant,
a 20-min visit from a Community Nurse and a GP tele-
phone consultation. Following treatment discontinuation,
50 % of patients are attributed the cost of a weekly GP visit
[21].
Utility estimates
The quality and applicability of utility data varied across
previous health economic studies. Ikenberg et al. [13]
reported EQ-5D utility data from 15-week trials of com-
peting opioid regimen patients (n[ 1000) with chronic
pain [23]; these data have also been used to capture the
HRQL in two other studies in the review [14, 18]. Else-
where, Dunlop et al. [17] reported the only other economic
evaluation in which generic preference-based HRQL data
from patients in the effectiveness trial were available to
inform the analysis. However, the data, from over 300 non-
cancer pain patients [24] were analysed by treatment arm
and time since randomisation and reported by categories
incompatible with the reference model structure [17].
In the model built to inform guidelines for opioid use in
palliative care [10], the NICE GDG used an HRQL esti-
mate for controlled pain from a standard gamble study of
95 patients with chronic non-cancer pain [25], a source
used to inform utility assumptions in two further economic
studies [12, 16]. The earliest economic evaluations in the
review [6, 11] derived utility estimates for controlled and
uncontrolled pain from another standard gamble study,
whose sample of 114 participants was drawn from the
general population [26]. More recently, Neil et al. used SF-
6D data from a multisite study of 96 non-cancer pain
patients to inform utility estimates for adequate and inad-
equate pain relief [5]. Of the two remaining economic
studies in the review, Hass et al. [15] used general popu-
lation HRQL data to capture baseline utility and assigned
fracture-related utility decrements, while Frei et al. [7] did
not consider HRQL, measuring outcomes as ‘days of good
pain control’.
Table 4 shows the utility data used in the model. The
categories reported by Ikenberg et al. [13], derived from
EQ-5D utility data from 15-week trials of competing opi-
oid regimens reported by over 1000 chronic pain patients,
map to the four model states associated with one treatment
line in the reference model and are reasoned to be the most
appropriate available from the studies reviewed for this
exploratory analysis. These estimates are used for first-line
treatment states.
Patients’ HRQLs are likely to fall as they experience
failed treatment lines. To reflect this in the absence of a
Table 3 Parameter estimates
for model costs
Parameter description Estimate Source
Treatment cost per cycle,
morphine
£2.63 BNF 67 [22]; NICE [10]
Co-medication cost per cycle,
morphine
£2.26 NICE [10]; Curtis et al. [21]
Treatment cost per cycle,
oxycodone
£9.20 BNF 67 [22]; Dunlop et al. [17]
Co-medication cost per cycle,
oxycodone
£0.04 Dunlop et al. [17]; Curtis et al. [21]
Treatment cost per cycle, novel
therapy
£55.21 Assumption: 6 times oxycodone treatment cost
Co-medication cost per cycle,
novel therapy
£0.03 Assumption: proportional reduction of 0.3 relative to
oxycodone
Adverse event cost per cycle £6.99 NICE [10]; Curtis et al. [21]
Cost associated with withdrawal £106.91 NICE [10]; Curtis et al. [21]
Treatment discontinuation cost per
cycle
£18.50 Assumption: Half discontinued patients visit GP weekly;
Curtis et al. [21]
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robust estimate of this effect, the model applies a multiplier
of 0.9 to the estimates shown in Table 4 for corresponding
second-line model states. Treatment discontinuation is
attributed the lowest utility estimate in Table 4, adjusted by
an assumed multiplier of 0.8 to reflect the negative effect of
successive failed treatments upon HRQL. These assump-
tions are however easily challenged; the importance of
assumptions about lasting HRQL effects of failed treatment
lines is explored as a scenario, as described in ‘‘Scenario
analyses’’.
Scenario and sensitivity analyses
Scenario analyses
The exploratory analysis using the reference model was
based on a primary analysis using a defined base case
scenario: scenario 1 in Table 5. An additional six mod-
elling scenarios (scenarios 2–7 in Table 5) were used to
test the sensitivity of reference model outcomes to struc-
tural and parameter uncertainty not routinely analysed in
economic models of chronic pain.
Sensitivity analyses
In previous models, in the absence of adequate data
describing parameter uncertainty, assumptions have been
necessary and have typically been based on expert opinion.
However, the choice and magnitude of each assumption
and its importance for results have rarely been fully justi-
fied or tested.
To characterise and assess the potential variation in
model results stemming from underlying uncertainty
around input parameter estimates, probabilistic sensitivity
analysis (PSA) was performed using 1000 draws of input
values from assumed parameter distributions. It was pos-
sible to estimate uncertainty around utility and cycle
probability estimates from data reported by Ikenberg et al.
[13]. For other cycle probability and cost estimates, in the
absence of data, assumptions were required about the shape
and scale of uncertainty around parameter values. Utility
and cycle probability parameters were assumed to follow a
beta distribution (bound between 0 and 1). Costs were
assumed to follow a gamma distribution (non-negative and
positively skewed). In previous models, particularly when
expert opinion data have been used, similar assumptions
have been necessary, but the choice of assumption and its
importance for results have not been justified or tested.
Finally, to explore the importance of assumptions about
unknown parameter uncertainty, two alternative PSA runs
were undertaken, assuming unknown standard errors at 50
and 10 % of the parameter estimate values, respectively.
To understand key model drivers, one-way sensitivity
analyses (OWSA) were also performed. The OWSA esti-
mated the influence of changing each uncertain parameter
value between upper and lower boundaries upon the esti-
mated incremental net benefit (INB) of novel therapy. The
INB is a useful measure in sensitivity analyses when esti-
mated outcomes can vary between positive and negative
values and distort ICER (ratio) estimates, but requires a
fixed willingness to pay for an additional QALY. The INB
of novel therapy versus morphine is calculated here as the
estimated incremental QALYs of novel therapy multiplied
by a willingness to pay of £20,000 minus the estimated
incremental costs of novel therapy. Again, two separate
OWSA runs were undertaken, whereby one assumed
unknown standard errors to be 50 % of the parameter
estimate and another assumed unknown standard errors to
be 10 % of the parameter estimate to demonstrate in
addition the potential influence of distributional assump-
tions upon OWSA results in previous models.
Results
Per-patient costs and quality-adjusted life years (QALYs)
are the primary model outcomes. This exploratory analysis
presents results across the two model arms described above,
labelled in tables and figures as ‘morphine’ and ‘novel
therapy’. Results are presented in terms of primary model
outcomes and incremental outcomes across model arms.
Scenario analyses
Table 6 shows results from the scenario analyses. The base
case comparison between the novel therapy and morphine
Table 4 Parameter estimates
for model utility values
Parameter description Estimate Source
Utility, on treatment, no AEs 0.695 Ikenberg et al. [13]
Utility, on treatment, tolerable AEs 0.583 Ikenberg et al. [13]
Utility, withdrawn from treatment due to AEs 0.503 Ikenberg et al. [13]
Utility, withdrawn from treatment due to other reasons 0.405 Ikenberg et al. [13]
Utility multiplier, failed 1st-line treatment 0.900 Assumption
Utility multiplier, failed 2nd-line treatment 0.800 Assumption
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as first-line treatments for chronic pain predicts novel
therapy to produce a utility gain, 0.067 more per-patient
QALYs, but at a per-patient cost of over £1250. The
resulting incremental cost-effectiveness ratio (ICER) for
novel therapy versus morphine, which is the incremental
cost over the incremental effect (QALY gain), is just over
£19,125. In England and Wales, though NICE Appraisal
Committees do not use a specific cost-effectiveness
threshold, health technologies with a most plausible ICER
of less than £20,000 per QALY gained are generally con-
sidered cost-effective, though mitigating issues including
the degree of uncertainty around the ICER estimate are also
considered [27]. Elsewhere in the UK and across Europe,
similar approaches to health technology are prevalent, with
the willingness to pay for an additional QALY varying
according to jurisdiction-specific issues and budgetary
constraints. This suggests a price of six times the price of
oxycodone (and over 20 times the price of morphine)
would be justified by a 30 % improvement in tolerability
and effectiveness versus oxycodone. This ICER changes
when structural and data assumptions in the model are
altered, so the base case needs to be interpreted with
caution.
When assumptions about the care pathway beyond the
first line are altered (scenarios 2 and 3) the ICER estimate
varies substantially. The model state ‘‘Subsequent treat-
ment’’ is associated with a lower cycle cost and higher
utility tariff than ‘‘Treatment discontinuation’’, and
accordingly per-patient costs are lower while QALYs are
higher across both model arms in scenario 2 compared to
scenario 1. Despite this adjustment being applied to both
model arms, due to higher withdrawal rates in the mor-
phine arm, the ICER increases to nearly £25,900 in sce-
nario 2.
Table 5 Reference model—scenario descriptions
Reference Description
Scenario 1: ‘‘Base case’’ The model time horizon is 1 year and two lines of treatment are considered
Morphine is compared to the novel therapy as a first-line treatment
The cost and HRQL implications of drug titration and stabilisation are not modelled
After withdrawal from 1st-line therapy, patients on either model arm either discontinue
treatment or switch to oxycodone treatment
After withdrawal from 2nd-line therapy, all patients are assumed to discontinue treatment
Scenario 2: ‘‘3rd-line treatment with
morphine’’
Explores the consequences of different assumptions about subsequent treatment lines for model
results, as scenario 1 with the exception that: Following withdrawal from 2nd-line treatment,
90 % of patients move to a subsequent 3rd-line treatment. The cycle costs attributed to the
‘‘Subsequent treatment’’ health state are set to morphine treatment; the utility tariff attributed
to this health state is the average of the four utility estimates in Table 4, multiplied by 0.8 to
represent an assumed reduction in patient HRQL (having experienced two failed treatment
lines)
Scenario 3: ‘‘Morphine as 2nd-line treatment
on novel therapy arm’’
Explores the consequences of different assumptions about treatment pathways following 1st-
line treatment across both model arms, as scenario 1 with the exception that: Novel Therapy
patients are assumed to switch to morphine as opposed to oxycodone as a 2nd-line therapy
Scenario 4: ‘‘Titration and stabilisation’’ Explores the consequences of different assumptions about titration and stabilisation, as Scenario
1 with the exception that: For the first 4 weeks of 1st-line treatment, drug doses and AE
probabilities are adjusted in line with clinical data from previous studies (Ikenberg et al. [13]
reported doses of around two-thirds of the maintenance dose and withdrawal rates over twice
as high as those observed during maintenance therapy, during the first 4 weeks of treatment in
their study). Withdrawal rates are doubled and treatment costs multiplied by 0.65 in the first
four model cycles
Scenario 5: ‘‘Improvement in analgesic
effect’’
Explores the consequences of different assumptions about achieving pain control superiority, as
scenario 1 with the exception that: Utility values for patients receiving 1st-line novel therapy
are increased by 5 % to reflect improved levels of pain control when on treatment and
responding. Future generations of pharmacological therapies for chronic pain may offer
analgesic improvement which directly affects patient HRQL outcomes
Scenario 6: ‘‘2-year time horizon’’ Explores the consequences of different assumptions about the time horizon, as Scenario 1 with
the exception that: The time horizon is set to 2 years rather than 1 year. Extrapolation of data
over time has been routinely practiced in the majority of models but involves implicit
assumptions. The consequences of choice of time horizon has not always been robustly tested
in previous models, and results from scenario 6 will explore the consequence of simple
extrapolation of assumptions over time for model outcomes
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In scenario 3, patients in the novel therapy arm are
assumed to receive morphine, not oxycodone, as a second-
line therapy. The input data used imply a lower cost but
higher withdrawal rates for morphine versus oxycodone,
the base case second-line treatment, and total costs and
QALYs on the novel therapy arm are reduced accordingly
in scenario 3. As a result, the estimated ICER increases to
over £26,500. When there is uncertainty about the treat-
ment pathway, it is clearly important to explore how such
uncertainty may affect results.
In scenario 4, costs and treatment costs and cycle
probabilities of withdrawal were adjusted for the first four
model cycles to capture the lower treatment dose and
increased withdrawal rates observed in clinical practice
during the titration period. Per-patient QALYs are reduced
across both arms relative to scenario 1, reflecting higher
withdrawal rates in the first 4 weeks of treatment. Per-pa-
tient costs are lower than the base case for the novel
therapy arm and reduced to a lesser extent in the morphine
arm. This is explained by the higher treatment costs of
novel therapy versus oxycodone and oxycodone versus
morphine and the relative treatment cost savings from a
proportional reduction in dose across model arms during
the titration and stabilisation phase. The ICER is reduced
by nearly £5000 compared to scenario 1.
In scenario 5, the 5 % improvement in utility attributed
to first-line treatment with novel therapy to reflect a
potential improvement in analgesia leads to a 50 %
increase in the incremental QALYs associated with the
novel therapy arm compared to the base case in scenario 1.
As a result, the ICER estimate is driven down by over
£4000. Forthcoming therapeutic agents may offer analgesic
benefit, and this could clearly have a substantial impact
upon cost-effectiveness estimates.
In scenario 6, the model time horizon was increased to
2 years. This caused the ICER estimate to fall to just under
£12,200. After 1 year, the base case model estimates that
over 50 % of patients will still be receiving either first- or
second-line therapy in the novel therapy arm, whereas this
figure is\30 % in the morphine arm. The relative benefit
Table 6 Scenario analysis
results
Outcome Morphine Novel therapy Incremental, novel therapy
versus morphine
Scenario 1: ‘‘Base case’’
Costs 845.3130 2126.7532 £1281.44
QALYs 0.505 0.572 0.067
ICER £19,126.66
Scenario 2: ‘‘3rd-line treatment considered’’
Costs £652.18 £2022.08 £1369.90
QALYs 0.536 0.589 0.053
ICER £25,899.20
Scenario 3: ‘‘Morphine as 2nd-line treatment on novel therapy arm’’
Costs £845.31 £2125.49 £1280.18
QALYs 0.505 0.554 0.048
ICER £26,550.64
Scenario 4: ‘‘Titration and stabilisation’’
Costs £874.29 £1867.79 £993.50
QALYs 0.490 0.561 0.070
ICER £14,170.81
Scenario 5: ‘‘Improvement in analgesic effect’’
Costs £845.31 £2126.75 £1281.44
QALYs 0.505 0.591 0.085
ICER £15,000.22
Scenario 6: ‘‘2-year time horizon’’
Costs £1787.01 £3390.83 £1603.82
QALYs 0.864 0.996 0.132
ICER £12,182.50
Scenario 7: ‘‘No assumed HRQL decrement over successive treatment lines’’
Costs £845.31 £2126.75 £1281.44
QALYs 0.557 0.603 0.046
ICER £27,970.41
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of receiving novel therapy versus morphine as a first-line
treatment resonates beyond 1 year; this highlights how
assumptions used to extrapolate data in economic models
can be of importance for study results.
In scenario 7, ignoring potential lasting reductions in
patient HRQL associated with experiencing treatment
failure leads to a 30 % reduction in the expected incre-
mental QALY gain associated with the novel therapy,
compared to the base case. As a result, the ICER estimate is
increased to nearly £28,000. Model results are clearly
highly sensitive to assumptions about patient HRQL, an
area in which data are lacking.
Sensitivity analyses
Figure 2 shows scatterplots of 1000 PSA ICER estimates
where the standard error of parameter point estimate values
with unknown distributions is assumed to be 50 % of the
parameter point estimate. Figure 4 shows the correspond-
ing PSA ICER estimate scatterplot where these standard
errors are assumed to be 10 % of the parameter point
estimate. Figures 3 and 5 show CEACs produced using the
data presented in Figs. 2 and 4, respectively.
Comparing Figs. 2 and 3 with Figs. 4 and 5, it is clear
that assumptions about the scale of uncertainty around
parameter estimates can influence the apparent uncertainty
around model outcomes. Viewing Figs. 2 and 3, the
incremental QALY gain associated with novel therapy
ranges from -0.07 to over 0.19 across PSA draws and at a
willingness to pay of £30,000 for an additional QALY, the
probability novel therapy is preferable to morphine as a
first-line treatment is shown to be 74 %. By contrast,
Figs. 4 and 5 show no PSA draw at which the morphine
arm produced the greater estimated health outcome and
suggest a 98 % probability that novel therapy is preferable
to morphine as a first-line treatment, at a willingness to pay
of £30,000 for an additional QALY. Where previous
models have suggested their results are robust to sensitivity
tests this may have been primarily due to underestimates of
uncertainty around highly uncertain parameters.
Figures 6 and 7 show tornado diagrams presenting
results from the OSWA run under different assumptions
about the scale of uncertainty around parameter estimates.
The model is sensitive to uncertainty around the HRQL of
patients on first-line treatment who are not experiencing
tolerable AEs, which is wide as only 215 patients in the
sample of Ikenberg et al. [13] informed this estimate. The
relative and absolute importance of uncertainty around
cycle probabilities of treatment withdrawal is clearly
determined by assumptions about the scale of parameter
uncertainty in Figs. 6 and 7. Where previous models have
suggested that their results are insensitive to changes in
highly uncertain parameter inputs, this may have been
primarily due to arbitrary assumptions about the scale of
uncertainty around parameter estimates.
Discussion
The need across Europe to justify resource allocation
decisions based on economic value has placed a burden on
manufacturers to provide evidence of value using robust
modelling approaches and data. In an area such as chronic
pain management, key robust data are scarce, so this task is
Fig. 2 Scatterplot of base case
cost-effectiveness pairs,
assuming 50 % standard errors
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more difficult. In order to increase the chance of correct
societal resource allocation decisions and maintain incen-
tives for continued development of analgesic technologies,
it is vital that modelling approaches are both transparent
and robust.
The systematic literature review identified key areas of
modelling variability and reliance on assumptions in pre-
vious chronic pain models. Past models have varied in their
structural complexity; more complex models have gener-
ally been reliant on expert data to inform model parameters
to a greater extent. The scenarios explored in this study
using the de novo reference model highlight how certain
structural and data assumptions may have influenced cost-
effectiveness results in previous economic evaluations of
treatments for chronic pain. Economic evaluations are a
necessary medium to justify price premiums for novel
therapies, but European decision bodies such as NICE may
have been distrustful of previous model results because of
the absence of robust exploration of the implications of
uncertainty around these assumptions. Though non-specific
in their criticism in a review of evidence for opioids in
palliative care, a NICE GDG described three studies
identified here [6, 11, 12] as subject to potentially serious
limitations [10]. Each of these studies required assumptions
and expert opinion to structure and parameterise their
model; if the uncertainty around these assumptions had
been robustly explored, the NICE GDG may have found
evidence from previous studies of far more use.
Fig. 3 Cost-effectiveness
acceptability curve using the
Fig. 2 results
Fig. 4 Scatterplot of base case
cost-effectiveness pairs, base
case, assuming 10 % standard
errors
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Different structural and parameter assumptions explored
in this study were shown to influence cost-effectiveness
estimates, with the deterministic ICER estimate ranging
from around £12,000 when a time horizon of 2 years was
used to over £25,000 when different assumptions about the
care pathway were explored. There is variation in treatment
patterns for chronic pain, and it is clearly vitally important
that the consequences of this variation and uncertainty are
robustly tested in future economic models.
The economic evaluations of chronic pain therapies
identified in the systematic literature review considered
opioid therapies only. Perhaps due to the trial design in
opioid studies, whereby dosing is carefully adjusted to
balance the analgesic effect with tolerability, in previous
models the incremental value between treatments has been
judged on utility gain from differences in the tolerable and
intolerable adverse event rate rather than differences in the
analgesic effect. Common practice has instead been to
account for differences in analgesia more crudely by
accounting for withdrawal due to efficacy. Future therapies
may also offer improvements in analgesia, regardless of
dose. This study has explored the consequences of a rela-
tive improvement in analgesic effect for one treatment
versus another for cost-effectiveness estimates, and the
results suggest that cost-effectiveness estimates are sensi-
tive to relative utility scores across comparator arms.
However, it may be important in future studies to robustly
quantify with greater sensitivity the relationship between
pain outcome measures, such as the widely used 11-point
numerical rating scale (NRS), and patient HRQL. Two
previous studies have investigated the relationship between
the EQ-5D and the 11-point NRS in general population
Fig. 5 Cost-effectiveness
acceptability curve using the
Fig. 4 results
Fig. 6 Tornado diagram of the top ten most influential parameters from OWSA, assuming 50 % standard errors
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(n = 100) [28] and neuropathic pain patient (n = 284) [29]
samples.
The analysis presented here is subject to limitations.
The input data for the reference model were sourced from
the systematic review of previous economic analyses, and
these were likely not ultimately the best available input
data for a definitive HTA model in pain. Nevertheless, the
plausibility of inputs has been validated by a clinical
expert. Future research could involve greater exploration
of the treatment pathway—particularly differences
between geographies. Further, several previous studies
have identified input data through systematic searches [6,
10, 12, 13, 18] yet were still reliant on expert opinion
data to varying degrees. Data availability from previous
models may be a strong indicator of data availability in
the field. In addition, though this study has sought to
identify and test assumptions around key decision points
in the modelling of chronic pain, the importance of dif-
ferent methodological approaches that vary across juris-
dictions, such as consideration of indirect costs, has not
been tested. Calculating indirect costs related to pain is a
very important area of future research, particularly given
many patients suffering from pain are of working age and
the high prevalence of chronic pain in the general
population.
Economic evaluation to inform treatment choices in
chronic pain is important but challenging, not least because
of data limitations. This study has highlighted the pressing
need for better knowledge on outcomes for patients after
they withdraw from treatment. Trial designs to capture
patient HRQL and other outcomes over multiple treatment
lines would be of great value. If expert opinion is required,
it is also important that the method of elicitation is robust;
guidance and recommendations for expert elicitation in
health economics are available [30]. Finally, further ver-
sions of chronic pain models could account for other
important differentiators of pain therapy—addiction/abuse
potential and respiratory depression being just two
examples.
Conclusion
Due to data limitations characteristic to chronic pain, it is
critically important that future models in chronic pain are
designed to be fully transparent in order to aspire to a
common approach to modelling pain and must include a
robust and well-designed set of reported sensitivity anal-
yses. This is important for fair and consistent decision
making from both the patient perspective and also those
needing to invest in new therapies. We hope that the open-
source reference model structure, as reported in this arti-
cle, can act as the initial step in the development of a
more consistent and transparent reference point for the
development and assessment of future economic models in
pain.
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